Status:

COMPLETED

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

Lead Sponsor:

Medical University of South Carolina

Collaborating Sponsors:

Emory University

Conditions:

Liver Failure

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The purpose of this study is evaluate the medication vasopressin for its ability to preserve kidney function in patients undergoing liver transplantation.

Detailed Description

Renal failure is a common complication of liver disease. Hepatorenal syndrome is caused by a dysfunctional global circulation in the setting of liver disease: Increased flow to the mesenteric circulat...

Eligibility Criteria

Inclusion

  • \> 18 years of age
  • undergoing liver transplant
  • ability to provide informed consent. If patient is unable to give informed consent i.e. hepatic encephalopathy, consent may be obtained from the patient's legally authorized representative

Exclusion

  • \< 18 years of age
  • renal failure

Key Trial Info

Start Date :

July 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2011

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT00886262

Start Date

July 1 2007

End Date

August 1 2011

Last Update

October 17 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant | DecenTrialz